Common menu bar

Breadcrumb

Perfluorooctane Sulfonate - Screening Assessment Report

Table of contents open. This index can be closed by clicking the following hyperlinked triangle.
Page
Synopsis
Introduction
1.0 Identity, Uses, and Sources of Release
2.0 Environmental Fate, Exposure and Effects
3.0 Environmental Concentrations
4.0 Key Toxicological Studies
5.0 Risk Quotient Analyses
6.0 Discussion
7.0 Conclusion
8.0 Reference
Table 1. Selected physical and chemical properties
Table 2. Summary of available data
Table 3. Range of BCF/BAF/BMF data
Appendix 1. List of PFOS
Appendix 2. PFOS Concentrations in Selected Wildlife
Appendix 3. Risk Quotients for Migratory Birds
Appendix 4. Summary of Data used in Risk Quotient
Appendix 5. Risk Quotients for PFOS

**Appendix 5: Risk Quotients for PFOS Comparing Concentrations in South Hudson Bay Polar Bears to Effects in Laboratory Mammal Toxicity**
Test organism/ study type	Reference	Effect	Critical Effect Level	Concen- tration in Serum (CTV) (mg.L-1 serum)	Concentration in liver at critical effect (CTV) (µg.kg-1 ww liver)	AFa	ENEV (ug.kg-1 liver)	EEVb (µg.kg-1 liver)	Q (EEV/ ENEV)
Rat receiving 0, 0.5, 2, or 5 ppm PFOS-K salt in diet for 104 weeks (2 years)	Covance 2002	Microscopic changes in liver	LOEL (m/f) = 2.0 ppm diet (0.06 to 0.23 mg.kg-1 bw/d)	13.9 mg.L-1	40800 (40.8 µg.g-1)	100	408	3770	9.24
Monkeys administered 0.03, 0.15, 0.75 mg.kg-1 bw/d PFOS for 26 weeks	Covance Labs 2002a	Thymic atrophy, reduced serum HDLP, cholesterol, triiodot- yhronine, total bilirubin	LOEL (m/f) = 0.03 mg.kg-1 bw/d	14.5 mg.L-1	19800 (19.8 µg.g-1)	100	198	3770	19.04
2 Generation- rat- F0 dosing 0.1, 0.4, 1.6, 3.2 mg.kg-1 bw/d; oral gavage males: from 6 weeks before, to end of mating. females: from 6 weeks before mating through to the 21st day of lactation (DL21). F1: 0.1, 0.4 mg. kg-1 bw/d; oral gavage males: from 22 days after birth to the end of mating (started 90 days after birth). females: from 22 days after birth through to DL 21 (for F2).	Argus Research Lab 2000 #418- 008 (also cited as US EPA OPPT AR-226 0569)	F0 males: reduced body weight gains	F0 male: NOEL = 0.1 mg. kg-1 bw/d LOEL = 0.4 mg. kg-1 bw/d	10.5 mg.L-1 45.4 mg.L-1	84900 (84.9 µg.g-1) 176000 (176 µg.g-1)	10 40	8490 4400	3770	0.44 0.85
		F0 female: reduced body weight gains during precoh- abitation	F0 female: NOEL = 0.4 mg. kg-1 bw/d LOEL = 1.6 mg. kg-1 bw/d	18.9 mg.L-1 82 mg.L-1	58000 (58 µg.g-1) 184000 (184 µg.g-1)	10 40	5800 18400	3770	0.65 0.2
		F1: significantly reduced litter sizes and both viability and lactation indices. Reductions in development including delayed eye opening, surface righting, pinna unfolding and air righting reflex.	F1: NOEL = 0.4 mg. kg-1 bw/d LOEL = 1.6 mg. kg-1 bw/d	NA	57.6 ppm 70.4 ppm	10 40	5760 (5.76 pm) 1760 (1.75 ppm)	3770	0.65 2.14
Rat-Oral gavage 42 days precoh- abitation to day 21 of lactation; cross fostering study. Doses 0 and 1.6 mg.kg- 1 bw/d	Argus Research Lab 2000 #418-014	Maternal: LOEL decrease in body weight gain, reduced gestation time, delivery time and litter size Offspring: LOEL increased mortality, reduced body weight, increased hepatocyte peroxisomes, increased type II pneumo cytes and lamellar bodies in the lung.	Maternal LOEL at dose 1.6 mg.kg-1 bw/d Offspring LOEL at maternal dose of 1.6 mg.kg-1 bw/d (level in liver of offspring at this dose was 70.4 µg.g-1= 70400 µg.kg-1 from study ARL 418-008)		70400 (70.4 ppm)	40	1760	3770	2.14

^a AF of 10 applied for interspecies variability and lab-to-field extrapolation, multiplicative with generic factor of 10 for extrapolation from LOEC to NOEC OR study specific factor of 4 where study information was available.

^b EEV is maximum concentration of PFOS in Canadian polar bears, South Hudson Bay

Page 18

Side navigation (left column)

Proactive Disclosure

Footer

Date Modified:: 2010-06-04

Top of Page

Important Notices